Age, Biography and Wiki
Riccardo Cortese was born on 29 March, 1944 in Italy, is an entrepreneur. Discover Riccardo Cortese's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 79 years old?
Popular As |
N/A |
Occupation |
N/A |
Age |
79 years old |
Zodiac Sign |
Aries |
Born |
29 March, 1944 |
Birthday |
29 March |
Birthplace |
Siena, Italy |
Date of death |
27 April 2017 (aged 73) |
Died Place |
Basel, Switzerland |
Nationality |
Italy |
We recommend you to check the complete list of Famous People born on 29 March.
He is a member of famous entrepreneur with the age 79 years old group.
Riccardo Cortese Height, Weight & Measurements
At 79 years old, Riccardo Cortese height not available right now. We will update Riccardo Cortese's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Riccardo Cortese Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Riccardo Cortese worth at the age of 79 years old? Riccardo Cortese’s income source is mostly from being a successful entrepreneur. He is from Italy. We have estimated
Riccardo Cortese's net worth
, money, salary, income, and assets.
Net Worth in 2023 |
$1 Million - $5 Million |
Salary in 2023 |
Under Review |
Net Worth in 2022 |
Pending |
Salary in 2022 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
entrepreneur |
Riccardo Cortese Social Network
Instagram |
|
Linkedin |
|
Twitter |
|
Facebook |
|
Wikipedia |
|
Imdb |
|
Timeline
During his career, Cortese received many academic and professional recognitions. Among others, he was elected member of the Academia Europaea; associate foreign member of the Academie des Sciences; elected Member of the Council of the European Molecular Biology Organization; President of the Italian Society of Life Science (FISV); and recipient of the Assobiotec Award in 2017.
Cortese died in Basel, Switzerland on April 27, 2017 of metastatic cancer. He is survived by his wife of almost 50 years, Karen Jonkman, his daughter Irene, son Maurizio and five grandchildren.
In 2015, Cortese founded a new company, Nouscom, dedicated to the generation of anti-cancer vaccines.
The success of Okairos led to its acquisition by Glaxo-Smith Kline (GSK) in 2013; from that date the company changed its name to ReiThera, and continued independent work in the further development and manufacture of viral vector-based therapeutics and vaccines.
In his last years at IRBM, Cortese oversaw the development of a new approach to vaccines based on chimpanzee adenoviral vectors. This became the founding idea of Okairos, a biotech company that he founded in 2007 upon leaving IRBM.
In 1990, Cortese left EMBL to found and direct the Istituto di Ricerche di Biologia Molecolare (IRBM) in Pomezia (Rome, Italy), a joint venture between Merck and Sigma Tau, where he remained until 2006. In 2000, Merck bought out the shares it did not own in IRBM, making it a fully owned subsidiary.
In 1979 Cortese was recruited as Group Leader at the EMBL-Heidelberg, and subsequently established and directed the Gene Expression Programme (now the Genome Biology Unit).
In 1976 he took a post-doctoral position at the MRC Laboratory of Molecular Biology in Cambridge, England, where he forged lasting professional relationships with leading figures in Molecular Biology, including Max Perutz, John Gurdon, Fred Sanger and Sydney Brenner. While at the MRC, his research focus was the maturation of tRNAs in eukaryotic systems.
Riccardo Cortese received his medical degree in 1968 from the University of Naples, Italy. Shortly after, he joined the lab of Bruce Ames at the University of California Berkeley as a PhD student, where he studied transcriptional regulation and RNA post-transcriptional modification in bacteria. In 1973, he returned to Naples as an assistant professor at the Institute of Biochemistry of the II Medical School, where he pursued research efforts investigating post-transcriptional modifications of tRNA dealing in particular with tRNA pseudouridylation.
Riccardo Cortese (Siena, Italy, March 29, 1944 - Basel, Switzerland, April 27, 2017) was an Italian scientist, entrepreneur, and innovator in the field of gene expression, drug discovery and genetic vaccines. His work led to the development of novel therapeutic strategies for the prevention and cure of viral infections, including HIV, HCV, Ebola and RSV. He pioneered a novel platform technology based on simian adenoviral vectors for prophylactic and therapeutic vaccines, and authored more than 300 publications in peer reviewed journals in the field of gene expression, transcriptional control, molecular virology and immunology.